Stay Updated on the Latest Advancements in Immunotherapy
AIM with Immunotherapy reviews the latest medical publications to highlight stories related to treatment with immunotherapy in oncology.
Stay updated in the immunotherapy field with articles cultivated for you and listed by date from most to least recent. To read the articles, hover and click on the individual titles. The titles will link readers to articles on immune-related adverse events, FDA approvals of relevant therapies, health outcomes, and changes impacting clinical management of cancers treated with immunotherapy.
Priority is given to primary-sourced, full-length articles provided by the publishers without charge. Only a select few major, paradigm-changing updates of abstracts are included.
March 25, 2025
Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76K trial
March 19, 2025
FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1)
March 13, 2025
Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma
March 11, 2025
Blocking MIF secretion enhances CAR T-cell efficacy against neuroblastoma
March 7, 2025
Abstract Thinking and Statins With Immune Checkpoint Inhibitors: Enough to Change Clinical Practice?
March 8, 2025
Antibody-Drug Conjugates: The Toxicities and Adverse Effects That Emergency Physicians Must Know
March 3, 2025
Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study
March 1, 2025
A case of immune checkpoint inhibitor-related conjunctivitis controlled by tacrolimus eye drops
March 1, 2025
Hidradenitis suppurativa induced by ipilimumab and nivolumab: A rare association
February 12, 2025
Immune Checkpoint Inhibitors in Field Cancerization and Keratinocyte Cancer Prevention
February 10, 2025
Acquired Generalized Lipodystrophy as an Adverse Event of Combined Immune Checkpoint Inhibitor Therapy
February 6, 2025
Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer
February 3, 2025
Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer
February 3, 2025
Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas
January 9, 2025
Anti-CTLA-4 generates greater memory response than anti-PD-1 via TCF-1
January 7, 2025
Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB–D melanoma: a phase 1/2 trial
January 6, 2025
Ocular surface disease related to tisotumab vedotin-tftv
January 4, 2025
Gut microbiome and immune checkpoint inhibitor toxicity
December 30, 2024
Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma
December 27, 2024
FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injection
December 23, 2024
Immune Checkpoint Inhibitor–Induced Vitiligo-Like Depigmentation
December 18, 2024
Neoadjuvant Pembrolizumab in Stage I-III Deficient Mismatch Repair Colon Cancer: A Clinical Trial
December 16, 2024
TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation
December 13, 2024
FDA approves cosibelimab-ipdl for metastatic or locally advanced cutaneous squamous cell carcinoma
December 3, 2024
Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years
November 27, 2024
Nivolumab in Patients With Advanced or Metastatic Malignancies, Including Rare Cancers: Results of CheckMate 627, an Adaptive Basket Design Clinical Trial
November 27, 2024
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
November 21, 2024
Low-Dose Anti-PD(L)1 for the Treatment of Solid Malignancies
November 21, 2024
FDA grants accelerated approval to zanidatamab-hrii for previously treated unresectable or metastatic HER2-positive biliary tract cancer
November 20, 2024
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)
November 10, 2024
Management of Immunotherapy-Related Toxicities, Version 2.2024
November 8, 2024
FDA approves obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia
November 4, 2024
CAR T Cells and T-Cell Therapies for Cancer
October 30, 2024
Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinoma
October 29, 2024
Immune-mediated colitis after immune checkpoint inhibitor therapy
October 23, 2024
Combined PD-1 and CTLA-4 Blockade in an International Cohort of Patients with Acral Lentiginous Melanoma
October 18, 2024
Genetic Factors Associated with Clinical Response in Melanoma Patients Treated with Talimogene Laherparapvec: A Single-Institution Retrospective Analysis
October 16, 2024
Probiotic neoantigen delivery vectors for precision cancer immunotherapy
October 9, 2024
Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies
October 5, 2024
Thromboembolism during immune checkpoint inhibitor therapy: frequency and risk factors
October 3, 2024
FDA approves neoadjuvant/adjuvant nivolumab for resectable non-small cell lung cancer
October 2, 2024
MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution
September 20, 2024
Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial
September 16, 2024
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial
September 12, 2024
Five latent factors underlie response to immunotherapy
September 3, 2024
Neoadjuvant immune checkpoint blockade in women with mismatch repair deficient endometrial cancer: a phase I study
August 29, 2024
Clinical and pathological characterization of Tebentafusp-associated skin toxicity – a cohort study with 33 patients
August 29, 2024
Identification of Immune Checkpoint Inhibitor–Induced Diabetes
August 20, 2024
Predominance of hyper-progression in mucosal melanoma during anti-PD-1 monotherapy treatment
August 13, 2024
Single Institution Experience with Immune Checkpoint Inhibitors in Vulvar and Vaginal Melanomas
August 8, 2024
Health and Economic Outcomes of Pembrolizumab in the Treatment of Metastatic Non-small Cell Lung Cancer (mNSCLC) and Melanoma in Italy
August 8, 2024
Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity
August 7, 2024
Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials
August 6, 2024
Clinical features associated with immune checkpoint inhibitor nephritis: a single-center clinical case series
August 2, 2024
FDA grants accelerated approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma
July 23, 2024
Evaluation of safety outcomes between nivolumab regimens with differing dosing patterns
July 17, 2024
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial
July 16, 2024
Pre-existing autoimmune disease as a risk factor for immune-related adverse events in cancer patients receiving immune checkpoint inhibitors
July 4, 2024
Research progress on the impact of intratumoral microbiota on the immune microenvironment of malignant tumors and its role in immunotherapy
July 3, 2024
RELATIVITY-048: Triplet Immunotherapy Shows Activity in Untreated Advanced Melanoma
June 27, 2024
Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitors
June 26, 2024
Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness
June 19, 2024
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision
June 7, 2024
Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy
June 6, 2024
Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma
June 2, 2024
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
May 30, 2024
From decision to reflection: understanding the experiences and unmet care needs of patients treated with immunotherapy for melanoma in the adjuvant or metastatic setting
May 23, 2024
Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma: A Nonrandomized Controlled Trial
May 16, 2024
FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer
May 16, 2024
FDA Grants Accelerated Approval to Lisocabtagene Maraleucel for Relapsed or Refractory Follicular Lymphoma
May 8, 2024
Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy
May 1, 2024
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)
April 26, 2024
Risk of T-Cell and Second Primary Malignant Neoplasms After CAR T-Cell Therapy
April 23, 2024
Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways
April 22, 2024
Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort
April 22, 2024
Bispecific Immune Checkpoint Inhibitor Improves Survival in Patients With Gastric Cancer, Regardless of PD-L1 Status
April 17, 2024
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
April 7, 2024
Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial
April 3, 2024
Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis
March 28, 2024
Safety, efficacy, and biological data of T cell-enabling oncolytic adenovirus TILT-123 in advanced solid cancers from the TUNIMO monotherapy phase I trial
March 18, 2024
Senescence drives immunotherapy resistance by inducing an immunosuppressive tumor microenvironment
March 11, 2024
Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial
March 7, 2024
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study
March 1, 2024
Prediction of Effectiveness and Toxicities of Immune Checkpoint Inhibitors Using Real-World Patient Data
February 29, 2024
Unveiling cutaneous adverse events and prognosis in immunotherapy for melanoma and squamous cell carcinoma
February 29, 2024
Cancer neoepitopes viewed through negative selection and peripheral tolerance: a new path to cancer vaccines
February 24, 2024
Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy
February 23, 2024
Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial
February 21, 2024
FDA Adds Boxed Warning to CAR T-Cell Therapies, but Says Benefits Outweigh Risks of Secondary Cancers
February 19, 2024
Immune-related serious adverse events with immune checkpoint inhibitors: Systematic review and network meta-analysis
February 16, 2024
FDA Approves First One-time Cell Therapy for a Solid Tumor
February 16, 2024
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial
February 14, 2024
Pan-cancer proteogenomics characterization of tumor immunity
February 8, 2024
Association of Baseline Tumor-Specific Neoantigens and CD8+ T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors
February 5, 2024
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma
February 5, 2024
A case of ruptured hepatic metastases during pembrolizumab administration for cutaneous malignant melanoma
January 24, 2024
Immunotherapy eliminates senescent cells, making chemotherapy more efficientL: Study
January 22, 2024
Immunotherapy combination induces ‘robust’ responses in high-risk follicular lymphoma
January 20, 2024
First-Line Nivolumab Plus Ipilimumab Demonstrates Superior PFS in mCRC
January 16, 2024
End-of-Life Immunotherapy Use Increasing in Advanced Melanoma, RCC, NSCLC
January 16, 2024
Colorectal Cancer Patients May Continue to Benefit After Stopping Immunotherapy
January 15, 2024
FDA Approves Pembrolizumab Plus Chemoradiotherapy to Treat FIGO 2014 Stage III-IVA Cervical Cancer
January 13, 2024
Beta-Adrenergic Blockade in Advanced Non-Small Cell Lung Cancer Patients Receiving Immunotherapy: A Multicentric Study
January 11, 2024
Immunotherapy and Radiation Combo Shows Improved Outcomes for Non-small Cell Lung Cancer
January 7, 2024
Atezolizumab May Yield OS Benefit in PD-L1+ Advanced Urothelial Carcinoma
January 6, 2024
Determining Optimal IO Combinations in Advanced NSCLC
January 4, 2024
Anti-CTLA-4 nanobodies offer promising strategy to prevent colitis in cancer immunotherapy
January 3, 2024